Literature DB >> 21740672

Tuberculosis in human immunodeficiency virus infected Ugandan children starting on antiretroviral therapy.

S Bakeera-Kitaka1, A Conesa-Botella, A Dhabangi, A Maganda, A Kekitiinwa, R Colebunders, D R Boulware.   

Abstract

OBJECTIVE: To identify the incidence of tuberculosis (TB) in human immunodeficiency virus (HIV) infected children in a resource-limited setting before and after initiation of antiretroviral therapy (ART), and to assess the impact of TB screening by tuberculin skin testing and clinical history.
METHODS: A retrospective cohort study of 1806 HIV-infected children and adolescents (age <18 years) initiating ART from 2003 to 1 July 2006 in Kampala, Uganda. A TB screening program was instituted clinic-wide in January 2006.
RESULTS: Of 311 (17.2%) HIV-infected children, 171 had been diagnosed with TB before and 140 after ART initiation. During the first 100 days of ART, risk of a new TB diagnosis was 2.7-fold higher compared to the pre-ART period (RR 2.7, 95%CI 2.1-3.5, P < 0.001). After 100 days of ART, the TB incidence rate decreased to below pre-ART levels (RR 0.41, 95%CI 0.30-0.54, P = 0.002). After TB screening was instituted in 2006, the proportion of new TB cases diagnosed after starting ART decreased by 70% (95%CI 51-82, P < 0.001), abating the early excess risk.
CONCLUSIONS: TB is common among African children and adolescents initiating ART in sub-Saharan Africa. More aggressive screening for active TB before starting ART can diminish the rate of TB during immune reconstitution. Future studies are needed to determine optimal screening practices for HIV-infected children.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21740672      PMCID: PMC3325109          DOI: 10.5588/ijtld.10.0538

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  11 in total

1.  Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.

Authors:  Cordula Reitz; Ashraf Coovadia; Stephen Ko; Tammy Meyers; Renate Strehlau; Gayle Sherman; Louise Kuhn; Elaine J Abrams
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

Review 2.  Pulmonary disease in HIV-infected African children.

Authors:  S M Graham; J B Coulter; C F Gilks
Journal:  Int J Tuberc Lung Dis       Date:  2001-01       Impact factor: 2.373

3.  Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment.

Authors:  Marcel Yotebieng; Annelies Van Rie; Harry Moultrie; Stephen R Cole; Adaora Adimora; Frieda Behets; Tammy Meyers
Journal:  AIDS       Date:  2010-06-01       Impact factor: 4.177

4.  Tuberculosis in children dying with HIV-related lung disease: clinical-pathological correlations.

Authors:  W P Rennert; D Kilner; M Hale; G Stevens; W Stevens; H Crewe-Brown
Journal:  Int J Tuberc Lung Dis       Date:  2002-09       Impact factor: 2.373

5.  Age-related tuberculosis incidence and severity in children under 5 years of age in Cape Town, South Africa.

Authors:  S Moyo; S Verver; H Mahomed; A Hawkridge; M Kibel; M Hatherill; M Tameris; H Geldenhuys; W Hanekom; G Hussey
Journal:  Int J Tuberc Lung Dis       Date:  2010-02       Impact factor: 2.373

Review 6.  Tuberculosis in HIV-infected children.

Authors:  Soumya Swaminathan
Journal:  Paediatr Respir Rev       Date:  2004-09       Impact factor: 2.726

Review 7.  The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era.

Authors:  B J Marais; R P Gie; H S Schaaf; A C Hesseling; C C Obihara; J J Starke; D A Enarson; P R Donald; N Beyers
Journal:  Int J Tuberc Lung Dis       Date:  2004-04       Impact factor: 2.373

8.  A research agenda to promote the management of childhood tuberculosis within national tuberculosis programmes.

Authors:  P R Donald; D Maher; S Qazi
Journal:  Int J Tuberc Lung Dis       Date:  2007-04       Impact factor: 2.373

9.  HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort.

Authors:  Neil A Martinson; H Moultrie; R van Niekerk; G Barry; A Coovadia; M Cotton; A Violari; G E Gray; R E Chaisson; J A McIntyre; T Meyers
Journal:  Int J Tuberc Lung Dis       Date:  2009-07       Impact factor: 2.373

10.  Excellent outcomes among HIV+ children on ART, but unacceptably high pre-ART mortality and losses to follow-up: a cohort study from Cambodia.

Authors:  Marie-Eve Raguenaud; Petros Isaakidis; Rony Zachariah; Vantha Te; Seithabot Soeung; Kazumi Akao; Varun Kumar
Journal:  BMC Pediatr       Date:  2009-08-20       Impact factor: 2.125

View more
  23 in total

1.  Impact of expanded antiretroviral use on incidence and prevalence of tuberculosis in children with HIV in Kenya.

Authors:  L L Abuogi; C Mwachari; H H Leslie; S B Shade; J Otieno; N Yienya; L Sanguli; E Amukoye; C R Cohen
Journal:  Int J Tuberc Lung Dis       Date:  2013-10       Impact factor: 2.373

2.  Risk factors for mortality in Malawian children with human immunodeficiency virus and tuberculosis co-infection.

Authors:  W C Buck; D Olson; M M Kabue; S Ahmed; L K Nchama; A Munthali; M C Hosseinipour; P N Kazembe
Journal:  Int J Tuberc Lung Dis       Date:  2013-11       Impact factor: 2.373

3.  The burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa: a systematic review and meta-analysis.

Authors:  Olatunji O Adetokunboh; Ajibola Awotiwon; Duduzile Ndwandwe; Olalekan A Uthman; Charles S Wiysonge
Journal:  Hum Vaccin Immunother       Date:  2019-05-22       Impact factor: 3.452

4.  Prevalence of and risk factors for pulmonary tuberculosis among newly diagnosed HIV-1 infected Nigerian children.

Authors:  Augustine O Ebonyi; Stephen Oguche; Emeka U Ejeliogu; Oche O Agbaji; Nathan Y Shehu; Isaac O Abah; Atiene S Sagay; Placid O Ugoagwu; Prosper I Okonkwo; John A Idoko; Phyllis J Kanki
Journal:  Germs       Date:  2016-03-01

5.  Tuberculosis in human immunodeficiency virus-infected children starting antiretroviral therapy in Côte d'Ivoire.

Authors:  A F Auld; M Z Tuho; K A Ekra; J Kouakou; R W Shiraishi; G Adjorlolo-Johnson; R Marlink; T V Ellerbrock
Journal:  Int J Tuberc Lung Dis       Date:  2014-04       Impact factor: 2.373

6.  Mortality among pulmonary tuberculosis and HIV-1 co-infected Nigerian children being treated for pulmonary tuberculosis and on antiretroviral therapy: a retrospective cohort study.

Authors:  Augustine O Ebonyi; Stephen Oguche; Oche O Agbaji; Atiene S Sagay; Prosper I Okonkwo; John A Idoko; Phyllis J Kanki
Journal:  Germs       Date:  2016-12-02

Review 7.  Tuberculosis Immune Reconstitution Inflammatory Syndrome in children initiating Antiretroviral Therapy for HIV infection: A systematic literature review.

Authors:  Ruth Link-Gelles; Harry Moultrie; Shobna Sawry; David Murdoch; Annelies Van Rie
Journal:  Pediatr Infect Dis J       Date:  2014-05       Impact factor: 2.129

8.  Profiles of HIV-infected anti-retroviral therapy naïve children from Mumbai, India.

Authors:  Supriya Mayur Paranjpe; Purva Pankaj Sarkate; Nayana Avinash Ingole; Shweta Sadanand Raut; Preeti Rajeev Mehta
Journal:  World J Pediatr       Date:  2016-06-10       Impact factor: 2.764

9.  Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.

Authors:  Helen M McIlleron; Michael Schomaker; Yuan Ren; Phumla Sinxadi; James J C Nuttall; Hermien Gous; Harry Moultrie; Brian Eley; Concepta Merry; Peter Smith; David W Haas; Gary Maartens
Journal:  AIDS       Date:  2013-07-31       Impact factor: 4.177

10.  Survival of HIV-1 vertically infected children.

Authors:  Mary-Ann Davies; Diana Gibb; Anna Turkova
Journal:  Curr Opin HIV AIDS       Date:  2016-09       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.